Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a leading biotechnology company focused on transforming the treatment landscape for Inflammatory Bowel Disease (IBD). By leveraging cutting-edge antibody engineering, rational therapeutic combinations, and precision medicine, Spyre aims to develop next-generation IBD therapies. Two main forms of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD), which affect millions globally.
Founded in 2013, Spyre has been making significant strides in the field with a strong pipeline of investigational drugs targeting key molecules involved in IBD. The Company's lead candidates include SPY001 and SPY002, both of which are extended half-life monoclonal antibodies. SPY001 targets integrin α4β7, and SPY002 targets TL1A, showing promising results in preclinical studies. These candidates are set for presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) in February 2024.
Spyre's approach includes developing precision diagnostics to match patients with the most effective therapies. This method ensures that treatments are not only potent but also tailored to individual needs, enhancing efficacy and safety. The company is also investigating rational therapeutic combinations, which could offer comprehensive solutions for IBD patients.
Financially, Spyre is robust, having secured nearly $400 million in funding from top-tier investors. This financial strength supports their ambitious R&D programs and the anticipated start of Phase 1 clinical trials for SPY001 and SPY002. Spyre’s management team, led by CEO Cameron Turtle, DPhil., is committed to advancing their mission of developing best-in-class IBD treatments.
Recent corporate updates reveal a solid cash position with $485 million available as of March 31, 2024. This financial cushion ensures sustained operations and development activities well into 2027. Spyre continues to attract top talent, evidenced by recent stock option grants to new employees as part of their equity inducement plan.
For more information, visit Spyre's website or follow them on social media: @spyretx and LinkedIn.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in three major healthcare investor conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 13), the Stifel 2024 Healthcare Conference (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Live audio webcasts and replays will be accessible through Spyre's investor events website.
Spyre Therapeutics (NASDAQ: SYRE) announced accelerated timelines for SPY003, its novel half-life extended IL-23p19 monoclonal antibody, with first-in-human dosing now expected in Q1 2025. New data presented at UEGW showed SPY003's robust preclinical activity, including comparable potency and >3-fold half-life extension in NHPs relative to risankizumab. Spyre's portfolio now includes extended half-life molecules targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.
Additional preclinical data on SPY003 in combination with SPY001 or SPY002 demonstrated enhanced efficacy and pharmacodynamics. The company expects to share interim data from the accelerated first-in-human trial in H2 2025. Spyre also presented preclinical data on SPY001 (anti-α4β7) and SPY002 (anti-TL1A) at UEGW, supporting potential Q8-12W dosing regimens in IBD.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company focused on Inflammatory Bowel Disease (IBD) treatment, has announced the approval of inducement awards by its independent Compensation Committee. The awards include:
1. Stock options to purchase 400,000 shares of common stock granted to Dr. Sheldon Sloan, the new Chief Medical Officer.
2. Stock options to purchase an aggregate of 129,000 shares of common stock granted to four non-executive employees.
These equity inducement awards were approved on October 1, 2024, under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. The stock options have a 10-year term and an exercise price of $27.46, matching the closing price of Spyre's common stock on October 1, 2024. The vesting schedule includes 25% after one year and 1/48th monthly thereafter, subject to continuous service with Spyre.
Spyre Therapeutics (NASDAQ: SYRE) has appointed Dr. Sheldon Sloan as Chief Medical Officer. Dr. Sloan brings over 25 years of experience in pharmaceutical and biotech companies, with expertise in Inflammation and Immunology. His career includes leadership roles at J&J, Arena Pharmaceuticals, Pfizer, and Abivax.
Dr. Sloan's appointment comes as Spyre prepares to advance its programs into clinical trials over the next several months and initiate Phase 2 studies in 2025. His experience includes leading the Phase 3 development of obefazimod at Abivax and the development of etrasimod at Arena and Pfizer.
Spyre Therapeutics is focused on developing innovative therapies for inflammatory bowel disease (IBD) using antibody engineering, therapeutic combinations, and precision medicine approaches.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. The company's management will engage in a fireside chat on Wednesday, September 18, 2024, at 12:00 p.m. Eastern time.
Spyre Therapeutics specializes in antibody engineering, rational therapeutic combinations, and precision medicine approaches to improve IBD treatment efficacy and convenience. Investors and interested parties can access a webcast replay of the fireside chat on the company's investor events website for 90 days following the event.
Spyre Therapeutics (NASDAQ:SYRE) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
- Initiated Phase 1 trial of SPY001 (anti-α4β7 antibody) with interim data expected by year-end 2024
- SPY002 (anti-TL1A antibody) on track for first-in-human trials in H2 2024
- Nominated development candidate for SPY003 (anti-IL-23 antibody), with first-in-human trial expected in H1 2025
- $426 million in cash and equivalents as of June 30, 2024, with runway into 2027
- Q2 2024 R&D expenses: $32.6 million, up from $17.4 million in Q2 2023
- Q2 2024 net loss: $38.8 million, compared to $217.1 million in Q2 2023
The company is advancing its IBD pipeline with potentially best-in-class antibodies engineered for improved efficacy and convenience.
Spyre Therapeutics (NASDAQ: SYRE) announced the dosing of first participants in a Phase 1 trial for SPY001, a novel half-life extended anti-α4β7 antibody for treating Inflammatory Bowel Disease (IBD).
Preclinical data suggests improved dosing schedules, potentially every 8-12 weeks, compared to the standard biweekly dosing.
Interim pharmacokinetic and safety data are expected by year-end 2024.
Additionally, Spyre plans to begin first-in-human studies for SPY002, an anti-TL1A antibody, in the latter half of 2024.
All three targeted antibodies (α4β7, TL1A, IL-23) are expected to be in clinical trials within the next 12 months.
The Phase 1 trial will involve approximately 48 participants, focusing on safety and pharmacokinetics.
Spyre Therapeutics (NASDAQ: SYRE), a biotech firm focused on antibody engineering and precision medicine for Inflammatory Bowel Disease (IBD), announced the approval of stock options for 83,000 shares to three non-executive employees. These inducement awards were granted by Spyre's independent Compensation Committee under the 2018 Equity Inducement Plan. The options, approved on June 3, 2024, have a 10-year term with an exercise price of $36.79. They will vest and become exercisable gradually over four years, contingent on the employees' continuous service. This aligns with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ: SYRE), a biotechnology company specializing in antibody engineering and precision medicine for Inflammatory Bowel Disease (IBD), will participate in the Jefferies Global Healthcare Conference. The event will feature a fireside chat and investor meetings on June 5, 2024, at 9:30 a.m. Eastern time. The webcast will be available on the Spyre website for 90 days post-conference.
Spyre Therapeutics (NASDAQ: SYRE) has appointed Dr. Sandra Milligan to its Board of Directors. Dr. Milligan, currently President of Aspira Women's Health, brings extensive experience in clinical development and regulatory affairs, particularly in Inflammatory Bowel Disease (IBD). Her expertise is expected to aid Spyre as they advance their antibody therapies targeting α4β7 and TL1A into clinical studies. Dr. Milligan will replace Russell Cox, whose term ended on May 13, 2024. Jeffrey Albers has been appointed Chairman of the Board in connection with Cox's departure.
FAQ
What is the current stock price of Spyre Therapeutics (SYRE)?
What is the market cap of Spyre Therapeutics (SYRE)?
What is Spyre Therapeutics, Inc.?
What are the main products in Spyre's pipeline?
What recent achievements has Spyre made?
How is Spyre financially positioned?
Who is leading Spyre Therapeutics?
What is the significance of SPY001 and SPY002?
What is Spyre's approach to treating IBD?
How does Spyre plan to use recent funding?
What are the expected milestones for Spyre in 2024?
Where can I find more information about Spyre Therapeutics?
